OR2T27: A Potential Drug Target and Biomarker for Ovarian Cancer

OR2T27: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,120 new cases and 6,920 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains largely the same, with a 5-year survival rate of only 40%. Therefore, there is a urgent need for new treatments and better understanding of the underlying biology of ovarian cancer.

One potential drug target for ovarian cancer is OR2T27, a G protein-coupled receptor (GPCR) located on the surface of ovarian cancer cells. OR2T27 has been shown to play a role in the development and progression of ovarian cancer, and targeting this receptor has the potential to be a valuable new treatment for this disease.

OR2T27 is a small transmembrane protein that is expressed in various tissues, including the uterus, breast tissue, and brain. It is a member of the TGF-β receptor family, which is involved in cell growth, differentiation, and survival. OR2T27 is known to play a role in the regulation of cell proliferation and survival, and has been shown to be involved in the development and progression of ovarian cancer.

Studies have shown that OR2T27 is involved in the regulation of cell cycle progression, cell survival, and angiogenesis, which are all key factors in the development of ovarian cancer. For example, OR2T27 has been shown to promote the growth and survival of ovarian cancer cells, and to inhibit the production of cell cycle-related proteins that could potentially lead to a checkpoint in cell proliferation.

In addition to its role in cell biology, OR2T27 has also been shown to play a role in the development of ovarian cancer in animal models. For example, OR2T27-deficient mice have been shown to have reduced incidence of ovarian cancer, and overexpression of OR2T27 has been shown to promote the development of ovarian cancer in these mice.

Given the potential involvement of OR2T27 in the development and progression of ovarian cancer, targeting this receptor has the potential to be a valuable new treatment for this disease. Several studies have shown that inhibiting OR2T27 function can lead to a reduction in the growth and survival of ovarian cancer cells, and that this treatment has the potential to be both effective and safe.

One approach to targeting OR2T27 in ovarian cancer treatment is to use small molecules, such as inhibitors, that can inhibit OR2T27 function. These small molecules can be found in a variety of natural compounds, such as herbs, spices, and plants, and have been shown to have potential as new treatments for ovarian cancer.

Another approach to targeting OR2T27 in ovarian cancer treatment is to use antibodies that can selectively bind to OR2T27 and prevent it from interacting with its downstream targets. These antibodies can be used to block the function of OR2T27 in a variety of cellular processes, including cell cycle progression, angiogenesis, and cell survival.

In addition to its potential as a new drug target and biomarker, OR2T27 is also a potential biomarker for ovarian cancer. The expression of OR2T27 has been shown to be elevated in various tissues and fluids associated with ovarian cancer, including the blood, urine, and ovarian tissue. This suggests that OR2T27 may be a useful biomarker for the diagnosis and

Protein Name: Olfactory Receptor Family 2 Subfamily T Member 27

Functions: Odorant receptor

The "OR2T27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2T27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1